Velphoro is an iron-based drug used to treat hyperphosphatemia in adult patients with chronic kidney disease who are on dialysis [1]. It is a chewable tablet that binds to phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [1][2].
How does Velphoro work?
Velphoro contains ferric iron, which, when taken orally, reacts with dietary phosphate in the gut to form ferric phosphate. This compound is insoluble and is eliminated in the feces, thereby reducing phosphate absorption [1][2]. This mechanism helps to lower serum phosphate levels in patients [1].
What is hyperphosphatemia?
Hyperphosphatemia is a condition characterized by abnormally high levels of phosphate in the blood [3]. It is common in individuals with chronic kidney disease, particularly those on dialysis, because damaged kidneys are unable to effectively remove excess phosphate from the body [3]. High phosphate levels can lead to serious health problems, including cardiovascular complications, bone disease, and itching [3].
When does Velphoro's patent expire?
Information regarding the specific patent expiration dates for Velphoro is not publicly available in the provided text. However, for detailed patent information and timelines, resources like DrugPatentWatch.com can provide comprehensive data on drug patents and their expiry [4].
How does Velphoro compare to other phosphate binders?
Velphoro is an iron-based binder. Other classes of phosphate binders include calcium-based binders (e.g., calcium acetate, calcium carbonate) and non-calcium, non-iron binders (e.g., sevelamer, lanthanum carbonate) [2]. Iron-based binders like Velphoro offer an alternative mechanism for phosphate control and may have different tolerability profiles compared to other binder types [2].
What are the potential side effects of Velphoro?
The most common side effects reported with Velphoro include diarrhea, nausea, vomiting, constipation, and dark stools [1]. Dark stools are expected and are due to the iron content of the medication [1].
Who makes Velphoro?
Velphoro is manufactured by Vifor Pharma [1].
How should Velphoro be taken?
Velphoro is a chewable tablet and should be taken with meals or immediately after meals to ensure it can bind to dietary phosphate effectively [1]. Doses are typically adjusted based on serum phosphate levels [1].
What clinical data supports Velphoro's use?
Clinical trials have demonstrated Velphoro's efficacy in lowering serum phosphate levels in dialysis patients [1]. Studies have shown that Velphoro can effectively achieve and maintain target phosphate levels, and it has been compared favorably to other phosphate binders in terms of efficacy and tolerability [1][2].
Can Velphoro cause iron overload?
While Velphoro contains iron, the amount of elemental iron absorbed systemically is generally low. However, monitoring for iron overload may be considered in patients with underlying conditions that predispose them to iron accumulation [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204713s000lbl.pdf
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1304770
[3] https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/hyperphosphatemia
[4] https://www.drugpatentwatch.com/